Actively Recruiting
Detection of Viable CTCs Using the EPIDROP Technology in Metastatic Prostate Cancer (EPIDROP)
Led by University Hospital, Montpellier · Updated on 2025-07-10
100
Participants Needed
2
Research Sites
226 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The use of liquid biopsy could be the key for precision medicine. Circulating tumor cells (CTCs) are the most studied circulating biomarkers used to assess the metastatic process and they have shown their clinical validity and utility in cancer patients. However, their detection and capture are still a challenge as they are very rare in the bloodstream. In this clinical trial named "EPIDROP", the investigators will use an innovative device called EPIDROP (for EPIspot in a DROP) in metastatic prostate cancer. EPIDROP is a completely new technology answering to biological and clinical questions by proposing a procedure detecting the functional subset of prostatic CTCs at the single cell level. The investigators will stain cells in the sample for EpCAM, PSMA, CD45 before to encapsulate them one by one in microdroplets and measure the PSA secretion by only the viable CTCs. This study aims to demonstrate the non-inferiority of the EPIDROP compared to the CellSearch system.
CONDITIONS
Official Title
Detection of Viable CTCs Using the EPIDROP Technology in Metastatic Prostate Cancer (EPIDROP)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be male and at least 18 years old
- Have metastatic prostate cancer that is either untreated or in biological or clinical recurrence after hormone suppression (mCRPC)
You will not qualify if you...
- Have non-metastatic prostate cancer in biological or clinical recurrence after hormone suppression (nmCRPC)
- Have had another active or treated cancer within the last 5 years
- Be under legal protection such as guardianship or curatorship
- Be deprived of liberty by administrative decision
- Not be affiliated with or a beneficiary of a social security plan
- Be currently excluded from participation in another clinical trial
- Be unable to understand or respond to questionnaires
- Be unable to understand the nature, purpose, and methods of the study
- Refuse to sign informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University Hospital Center
Montpellier, Occitanie, France, 34295
Active, Not Recruiting
2
University Center, Hospital
Nîmes, France
Actively Recruiting
Research Team
C
Catherine ALIX-PANABIERES, MCU-PH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here